Annexon (ANNX) Stock Price, News & Analysis

Company Overview

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.

Key Stats

• Today's Range: $2.30 to $2.53
• 50-Day Range: $1.61 to $2.71
• 52-Week Range: $1.29 to $7.85
• Volume: 1.01 million shs
• Average Volume: 1.44 million shs
• Market Capitalization: $270.98 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $12.50
• Consensus Rating: Buy

Annexon Stock Analysis - MarketRank™

Annexon scored higher than 53% of companies evaluated by MarketBeat, and ranked 679th out of 936 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Annexon has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Annexon has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Annexon are expected to decrease in the coming year, from ($0.96) to ($1.06) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Annexon is -2.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Annexon is -2.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Annexon has a P/B Ratio of 0.90. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

10.47% of the float of Annexon has been sold short.

Short Interest Ratio / Days to Cover

Annexon has a short interest ratio ("days to cover") of 6.1.

Change versus previous month

Short interest in Annexon has recently increased by 1.50%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Annexon does not currently pay a dividend.

Dividend Growth

Annexon does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

10.47% of the float of Annexon has been sold short.

Short Interest Ratio / Days to Cover

Annexon has a short interest ratio ("days to cover") of 6.1.

Change versus previous month

Short interest in Annexon has recently increased by 1.50%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 3.3 / 5
• News Sentiment: 1.89

News Sentiment

Annexon has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.88 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Annexon this week, compared to 3 articles on an average week.

Search Interest

3 people have searched for ANNX on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, Annexon insiders have bought more of their company's stock than they have sold. Specifically, they have bought $10,123.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

12.67% of the stock of Annexon is held by insiders. A high percentage of insider ownership can be a sign of company health.

ANNX Stock Analysis - Frequently Asked Questions

How have ANNX shares performed this year?

Annexon's stock was trading at $5.13 at the beginning of 2025. Since then, ANNX shares have decreased by 51.9% and is now trading at $2.47.
View the best growth stocks for 2025 here.

How were Annexon's earnings last quarter?

Annexon, Inc. (NASDAQ:ANNX) announced its earnings results on Monday, May, 12th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.30) by $0.07.

When did Annexon IPO?

Annexon (ANNX) raised $150 million in an initial public offering on Friday, July 24th 2020. The company issued 10,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, BofA Securities and Cowen served as the underwriters for the IPO.

How do I buy shares of Annexon?

Shares of ANNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Annexon own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Annexon investors own include NVIDIA (NVDA), MercadoLibre (MELI), Advanced Micro Devices (AMD), Meta Platforms (META), CRISPR Therapeutics (CRSP) and Energy Transfer (ET).

Company Calendar

• Last Earnings: 5/12/2025
• Today: 7/01/2025
• Next Earnings (Estimated): 8/11/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ANNX
• CIK: 1528115
• Web: www.annexonbio.com
• Phone: 650-822-5500
• Fax: 650-636-9773
• Employees: 60
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $12.50
• High Stock Price Target: $14.00
• Low Stock Price Target: $11.00
• Potential Upside/Downside: +406.1%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.18)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$138.20 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -54.45%
• Return on Assets: -46.56%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 7.99
• Quick Ratio: 7.99

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.75 per share
• Price / Book: 0.90

Miscellaneous

• Outstanding Shares: 109,710,000
• Free Float: 95,813,000
• Market Cap: $270.98 million
• Optionable: Optionable
• Beta: 1.26